Can I Take Melatonin with Egrifta (Tesamorelin)?

Tesamorelin (brand name Egrifta, sold in the current formulation as Egrifta SV) is an injectable growth hormone-releasing hormone (GHRH) analogue approved by the FDA to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. Melatonin is an over-the-counter hormone supplement used for sleep. No pharmacokinetic drug interaction is expected between melatonin and tesamorelin, because the two compounds are cleared by different pathways and neither competes with the other for metabolism or transport. The relevant question is not whether the two substances interfere with each other's blood levels, but whether they push blood glucose regulation in the same or opposite directions when used together. That is a pharmacodynamic question, and it has not been studied directly in people taking both agents.

Melatonin and tesamorelin have no documented pharmacokinetic interaction: tesamorelin is broken down by proteolytic enzymes rather than the cytochrome P450 system, while melatonin is metabolized mainly through CYP1A2, so the two do not share a clearance pathway. The open question is pharmacodynamic. Tesamorelin raises growth hormone, which can reduce insulin sensitivity, and separate mechanistic and genetic research links melatonin receptor activity in pancreatic beta cells to reduced insulin secretion. No trial has tested the combination directly, so this is a plausible interaction inferred from two separate bodies of evidence, not a demonstrated one, and it supports a monitoring conversation rather than an outright restriction.

What tesamorelin does, and why glucose is the relevant axis

Tesamorelin stimulates the pituitary gland to release endogenous growth hormone, which in turn raises insulin-like growth factor 1 (IGF-1). Growth hormone physiologically opposes insulin's action in muscle and fat tissue, which is why glucose intolerance and new-onset hyperglycemia are recognized effects of tesamorelin therapy. This is documented in the FDA-approved prescribing information for Egrifta SV, which requires that glucose tolerance be assessed before starting treatment and periodically afterward (FDA label, accessed for the 2019 approved formulation). [1]

This is an FDA-labeled safety consideration, not a rare or theoretical side effect. It is the reason any other glucose-active substance, prescription or over-the-counter, deserves scrutiny in a patient on Egrifta.

What melatonin does to glucose regulation

Melatonin is not metabolically inert. Melatonin receptors (MT1 and MT2) are expressed on pancreatic beta cells, and receptor activation is mechanistically linked to reduced insulin secretion in laboratory and physiological studies. Human genetic studies of the melatonin receptor gene MTNR1B have associated reduced receptor signaling with altered fasting glucose and diabetes risk, which supports the idea that melatonin receptor activity has a real effect on glucose physiology in humans, not just in cell culture. Small human trials have reported that melatonin dosing before a glucose challenge can blunt insulin release and raise post-challenge glucose compared with placebo, with the effect appearing larger at higher doses.

We are not attaching specific effect sizes (for example, an exact percentage reduction in insulin secretion or an exact milligrams-per-deciliter glucose change) to this article, because the underlying papers cited in earlier drafts of this content could not be verified against the primary literature at the time of writing. A clinician or pharmacist who needs a precise magnitude for individualized counseling should pull the primary trial directly rather than rely on a secondhand number.

Does tesamorelin's pharmacokinetics matter here?

Tesamorelin is broken down by proteolysis rather than liver enzymes and bypasses cytochrome P450 metabolism entirely, giving it a short circulating half-life. Melatonin metabolizes primarily through CYP1A2. Since tesamorelin and melatonin do not compete for metabolic enzymes, transporters, or plasma-protein binding, neither can alter the blood concentration of the other through pharmacokinetic mechanisms. This explains why interaction databases list "no known interaction" between them. While this assessment of the pharmacokinetic relationship is accurate, it does not resolve the separate pharmacodynamic concerns discussed earlier and should not be construed as a comprehensive safety endorsement at all doses.

Does melatonin change how well Egrifta works?

Older, small physiological studies using intravenous melatonin reported an augmented growth hormone response to GHRH stimulation, which raised a theoretical question about whether melatonin could enhance tesamorelin's effect. Oral melatonin at typical over-the-counter sleep doses has low and variable bioavailability, and later work examining pituitary hormone responses to oral or lower-dose melatonin did not consistently reproduce a meaningful growth hormone stimulation. There is no basis in the available evidence for a patient or clinician to expect melatonin to meaningfully boost Egrifta's fat-reduction effect, and this angle should be treated as a physiological curiosity rather than a reason to add melatonin.

Evidence-status interaction assessment

What a clinician or pharmacist should verify before advising a patient

• Confirm the patient's current fasting glucose and HbA1c, and whether they were obtained before or after starting Egrifta.
• Confirm whether the antiretroviral regimen includes a CYP1A2 inhibitor or inducer, which could shift melatonin exposure independent of the glucose question.
• Ask about melatonin dose and formulation already in use; many OTC products contain 5 to 10 mg, well above physiologic replacement range.
• Do not rely on a "no known interaction" result from a drug-interaction checker as reassurance about the glucose question; that result reflects the pharmacokinetic picture only.
• If the patient has prediabetes or diabetes, route the decision to the prescribing clinician rather than defaulting to a fixed dose recommendation, since no validated dose threshold exists for this combination.

Practical considerations for patients already on Egrifta

Egrifta is injected once daily, and melatonin, when used, is typically taken shortly before bedtime. Because tesamorelin clears from circulation quickly after injection, the two are not present at peak plasma concentration at the same time. This does not remove the pharmacodynamic overlap, since tesamorelin's downstream effects on growth hormone and glucose regulation persist through the day regardless of when the peptide itself is measurable in blood. It does mean there is no reason to try to separate the timing of the injection and the supplement beyond normal daily routine.

Patients who start melatonin while on Egrifta should have a plan for follow-up glucose monitoring agreed with their prescriber, rather than assuming that a supplement purchased without a prescription requires no oversight. Warning signs that warrant contacting the prescriber promptly include a clearly elevated fasting glucose compared with the patient's own baseline, a new HbA1c result in the diabetic range, or new symptoms of hyperglycemia such as increased thirst, frequent urination, or unexplained fatigue. These are general hyperglycemia warning signs, not numeric thresholds validated specifically for this combination, and a patient experiencing them should seek medical evaluation rather than self-adjust the melatonin dose.

People with diabetes or prediabetes, and older adults

People with pre-existing diabetes or prediabetes are already candidates for closer glucose monitoring while on Egrifta, independent of melatonin. Adding a supplement that plausibly affects insulin secretion is a reasonable point to loop in the prescribing clinician before starting, rather than after. Endogenous melatonin production declines with age, and older adults may be more sensitive to exogenous melatonin's effects, which is a general pharmacologic consideration for melatonin use at any age and is not specific to Egrifta.

If melatonin feels like the wrong choice

Cognitive behavioral therapy for insomnia (CBT-I) is endorsed as first-line therapy for chronic insomnia by major clinical guidelines and produces no metabolic interactions, making it worth exploring before introducing supplements or sleep medications. Prescription sleep agents like low-dose doxepin present alternatives with their own interaction concerns, including effects on CYP2D6-dependent antiretrovirals, a consideration distinct from the glucose effects examined here. Changes to prescription sleep medications should be directed by the treating clinician and not undertaken independently.

What is established, what is plausible, and what remains unknown

Established: tesamorelin raises growth hormone and can impair glucose tolerance, and the FDA label requires glucose monitoring on that basis. Established: melatonin and tesamorelin do not share a metabolic clearance pathway, so no pharmacokinetic interaction is expected. Plausible but unproven: combining the two could produce an additive or synergistic effect on glucose intolerance in some patients, based on separate mechanistic and genetic evidence for each agent individually. Not established: any specific "safe" melatonin dose ceiling for Egrifta patients, or any benefit of melatonin to Egrifta's therapeutic effect. Readers and clinicians should treat numeric claims about exact magnitude of glucose change from combining these agents as unverified until traced to a primary trial, and should not extrapolate general melatonin-glucose findings to guarantee a specific outcome in an individual patient.

This article summarizes mechanism and general evidence for a supplement-medication combination and is not individualized medical advice. It has not yet completed qualified clinical review. Anyone taking tesamorelin (Egrifta) who is considering melatonin, especially with pre-existing diabetes, prediabetes, or a complex antiretroviral regimen, should discuss it with the prescribing clinician before starting.